Roche: FDA probing counterfeit cancer drug Avastin
Roche Holding AG is working with U.S. authorities to determine the source of counterfeit Avastin, purchased by at least 19 medical practices in the U.S. Roche and the Food and Drug Administration are seeking to prevent the fake cancer drug, which doesn't include the active ingredient bevacizumab, from being distributed further, the company's Genentech unit said in an e-mail late yesterday. The FDA notified the company about the issue in December, said Edward Lang, a spokesman for Roche's South San Francisco, California-based unit.
- Senators Hear How Two-Midnight Rule Harms Patients, Hospitals
- 3 Management Lessons from a Supermarket Debacle
- Medicare Advantage Carriers See 'No Choice' But to Accept Cuts
- Physicians to Appeal 'Docs v. Glocks' Ruling in FL
- IOM Identifies GME Problems, Calls for Finance Changes
- Healthcare Costs Start With What We Eat
- Revenue Cycles Get a Boost from Simple JPEG Files
- Handshaking Spreads Germs. Get Over It.
- CA Fines 8 Hospitals for Medical Errors
- Hospitals Likely to Outsource ICD-10 at Launch